Embed Size (px)
Citation preview
1
Funded by the European Union
The SME Instrument
Overseas Trade Fair Participation Programme
Supporting International Commercialisation of EU innovation
Meet our delegation of European Innovation Champions
BIO International Convention
19—22 June 2017
EU Pavilion - Booth #5837
2
Funded by the European Union
The SME Instrument
Overseas Trade Fair
Participation Programme
at BIO International
Convention!
Join us on the Horizon 2020 - SME
Instrument Pavilion to meet the 15 most
innovative EU companies at BIO
International Convention2017!
The EU’s successful Horizon 2020 - SME Instrument
programme offers innovative EU SMEs the
opportunity to commercialise their cutting-edge
innovations globally by exhibiting at major
international Trade Fairs. This time, 15 EU
Champions are present at BIO International
Convention!
The Overseas Trade Fair Participation programme is
part of phase 3 of the SME Instrument “Support to
commercialisation” funded by the EU’s Horizon
2020.
The overall objective of the programme is to
support the highly innovative SME Instrument
laureates in accessing overseas markets and allow
them to leverage business opportunities outside the
EU, further enhancing their growth potential.
This catalogue includes the profiles of the 15
thoroughly selected EU SMEs who are showcasing
their innovations at BIO 2017 in San Diego
International Convention Center.
The SME Instrument Overseas Trade Fairs Pavilion is
located on the EU Pavilion, Booth 5837. The
Overseas Trade Fairs Team and SMEs are looking
forward to meeting you!
For any queries about or meeting scheduling with
any of the EU Champions, please contact the
Overseas Trade Fairs Team via email.
Mr Jean-Jacques Lennon
Ms Laura Doumbouya
SME Instrument—Overseas Trade Fairs Team
ec.europa.eu/easme/
@H2020SME_OTF
CLINICAL LASERTHERMIA SYSTEMS AB | Sweden
ICOSAGEN CELL FACTORY | Estonia
P1VITAL PRODUCTS LTD | United Kingdom
PROACTINA SA | Greece
ABICH SRL | Italy
BBH BIOTECH POLSKA | Poland
IONOVATION GMBH | Germany
KLEINKLEIN GMBH | Germany
MIKRO BIYOSISTEMLER AŞ | Turkey
OAKBIO LTD | United Kingdom
PHARMAHUNGARY GROUP | Hungary
SIMFO GMBH | Germany
PARK-TECH SP. Z O.O. | Poland
TODOS MEDICAL | Israel
VIOMEDO | Germany
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
TABLE OF CONTENTS
3
Funded by the European Union
The company, which today is a public listed company
on the Nasdaq First North stock exchange in
Stockholm, Sweden, was founded in 2006 based on
research generated at Lund University and Skane
University Hospital by Prof. K-G Tranberg and his
group. The group discovered and published findings
indicating that cytotoxic thermal treatment of
tumours at temperatures below that of protein
denaturation would generate a significant anti-
tumour response and immunity in rats. Keeping the
tumour specific antigens (proteins) intact and
exposed to the immune system during and after a
thermal tumour ablation process may be the reason
for the significant immune response.
The company Clinical Laserthermia Systems (CLS) has
successfully developed the TRANBERG | Thermal
Therapy System and its portfolio of accessories,
designed for image guided high precision thermal
ablation procedures, including immune stimulating
interstitial laser thermotherapy (imILT).
CLS mission is to improve and expand the way
thermal ablation is being performed and used,
primarily, within interventional oncology, by offering
to the market a new improved high precision image
guided thermal ablation product. Through use of high
precision technology and research results of Prof.
Tranberg, CLS aims at expanding
the use of thermal ablation into patients with late
stage and metastatic disease. The expanded use is
aimed at inducing/improving systemic anti-cancer
response and immunity in patients not or partially
responding to SOC cancer immunotherapies.
Our product:
The company markets and sells its own TRANBERG |
Thermal Therapy System which is approved for local
tumour ablation and delivery of specific anti-tumour
immunity through immune-stimulating interstitial laser
thermotherapy (imILT) in Europe (CE-mark) and soft tissue
ablation in USA (510(k)). The TRANBERG | Thermal Therapy
System is developed around diode-laser technology and
laser delivery with intergraded tissue temperature feedback
system for higher precision during use. The system is
optimized for image guided interventional procedures
which include CT/US-guidance and include MR-inert 12 m
fibre optic laser applicators which makes it particularly
suitable for MR-guided procedures.
The TRANBERG | Thermal Therapy System includes both
capital equipment as well as sterile disposables. It is
intended for medical professionals within interventional
radiology, urology as well as surgery.
Our target audience:
CLS is reaching out to multinational and regional pharma
and biotech companies, academic centers, state and
regional biotech associations and service providers to the
industry within immune oncology, including financial and
consulting firms with the intent to initiate collaborations
leading to clinical evaluation of immune-stimulating
interstitial laser thermotherapy (imILT) in patients with late
stage and metastatic disease not or partially responding to
SOC cancer immunotherapies, such as check point
inhibitors.
Why us:
In 2016 CLS was awarded a European Union’s Horizon 2020
SME Instrument grant of 2.1 M€ for its project INTHER
725151.
CLS is a public listed company on the Nasdaq First North
stock exchange in Stockholm, Sweden.
Clinical Laserthermia Systems
AB | Sweden
www.clinicallaser.se
Dan J. Mogren
+46 4615 21 00
EU SME INSTRUMENT PHASE 2
EU contribution 2.136.358 €
INDUCING/IMPROVING SYSTEMIC ANTI-CANCER
RESPONSE AND IMMUNITY
Clinical Laserthermia Systems (CLS) develops and
markets minimal invasive products for image guided
soft tissue thermal therapy and ablation for the
interventional oncologist. The TRANBERG Thermal
Therapy System is intended and approved for local
tumor ablation and anti-tumour immune stimulating
interstitial laser thermotherapy (imILT) in Europe and
for soft tissue ablation in USA.
4
Funded by the European Union
We are passionate about producing recombinant
antibodies and challenging recombinant proteins in
mammalian cells, as well as developing premium
antibodies for research and in vitro diagnostics.
Icosagen mission is to enable its customers to focus
on the pre-clinical research of therapeutic antibodies
and other biologics by supplying high quality protein
and antibody candidates in a timely manner.
Our product:
Icosagen develops high affinity antibodies by using direct
cloning from b-cells of chickens, rabbits, or mouse
hybridomas (HybriFree technology). We have streamlined
the process by expressing VH/VL library as full IgGs in CHO
cells. Therefore, there are no surprises from the switch from
scFv to IgG, or from E.coli to mammalian expression.
Correct and high producing VH/VL pair can be discovered
within 4 weeks from an immunized animal.
The HybriFree Technology has several advantages:
· Fast: sequence information of the antigen-binding VH/VL
pair can be obtained in 6-7 weeks starting from the
immunization, and purified antibodies can be
delivered in as fast as 8-9 weeks
· Cost efficient: antigen-recognizing enrichment of B-cell
population reduces significantly size of antibody
library
· Manufacturability: B-cells are used for the in vivo
development, and CHO cells are used for the
screening of the full IgG or ScFv-Fc libraries
· Universal: antibodies can be reconstructed into different
subtypes, origins and structures
Icosagen provides antibody and recombinant protein
production services for pre-clinical research and in vitro
immunoassay development. We can start either from
antibody (or VH/VL) sequence information, hybridoma
cells, or cDNA. Our well established operating procedures
combined with our patented CHO-based expression system
guarantees:
· high quality (purity >98%, endotoxin levels <0,1 EU/mg)
· fast delivery (>3 weeks)
· elaborated report with detailed QC data.
· generation of stable episomal pool in 10 days for
reproduction runs.
Icosagen will be able to develop stable CHO cell lines for
the industrial production of recombinant proteins/
antibodies (starting from 2018).
Our target audience:
We would like to meet pharma and biotech companies
developing therapeutic and diagnostic antibodies, who
need to outsource the antibody development and non-
GMP manufacturing.
We give these companies an opportunity to focus on the
research of the antibody molecules by taking care of the
development and manufacturing of the antibodies.
Antibody manufacturing is done in Chinese hamster ovary
(CHO) cells that requires specialised equipment and know
how, and it is not reasonable for the pharma companies to
acquire and keep this competence in house. Therefore it is
common in the field to outsource the manufacturing and
development.
Why us:
Icosagen guarantees sharp timelines and high quality by
the well-established standard operating procedures, highly
qualified team and close communication with the
customer.
Icosagen has received a European Union’s Horizon 2020
SME Instrument grant of € 1.129.800 €, that places it
among top 7% of the most innovative small and medium
size companies in Europe.
Icosagen Cell Factory | Estonia
www.icosagen.com
Meelis Kadaja
+37 2737 70 80
EU SME INSTRUMENT PHASE 2
EU contribution 1.129.800 €
HIGH QUALITY PROTEIN AND ANTIBODY
CANDIDATES
Icosagen Cell Factory is developing and manufacturing
recombinant antibodies and proteins by using its
patented technologies. It produces antibodies/
antigens in up to gram-scale in 8 weeks and generate
production mammalian cell banks within 10 days. The
company is ISO 9001:2008 certified.
5
Funded by the European Union
P1vital® Products Ltd was founded in 2010 to focus
on the development of software products for the
pharmaceutical sector to improve the treatment of
mental and/or behavioural health disorders. Our vision
is to help transform the lives of mental health patients
throughout the world and be a market leader of
evidence-based, digital health solutions for both the
pharmaceutical and healthcare sectors. Our mission is
to provide high quality, cost-effective, reliable and
easy to use solutions for use by researchers, physicians
and patients. We build on scientific research and
collaborate with experts in academia and industry to
develop novel evidence-based behavioral assessments
to provide objective clinical outcome measures.
Our products:
P1vital®
ePRO Clinical is a secure integrated electronic data
capture solution for use in clinical trials measuring mental
health clinical outcomes. It provides questionnaires and
evidence-based behavioral assessments to be completed by
patients through web based or mobile devices, giving
freedom to collect data anywhere, in the clinic, on the move
or at home. It organizes and analyses clinical trial data,
facilitating compliance, data quality, and performance
monitoring.
The P1vital®
PReDicT Test is an online clinical decision tool,
a CE marked Class I medical device, to improve the
treatment of depression. It has the potential to significantly
improve patient outcomes, reduce healthcare costs and
reduce societal costs. The P1vital®
PReDicT Test could also
be used by the pharmaceutical sector as a companion
diagnostic.
Our target audience:
Clinical R&D professionals within the pharmaceutical sector
conducting clinical trials and interested in measuring mental
health clinical outcomes.
Partners who already have existing US market penetration in
which a synergistic relationship would be of mutual benefit.
Investors to support the US launch and commercialization
activities of our digital health products.
US healthcare providers to gain a better understanding of
routes to market for the P1vital®
PReDicT Test.
Why us:
P1vital has extensive knowledge and experience in the
mental health area, proven technology, and a successful
track record demonstrated through receiving a prestigious
European Union’s Horizon 2020 SME Instrument grant of
€4MM for developing the P1vital®
PReDicT Test, and
€1.2MM funding as a consortia member of the European
Union Innovative Medicines Initiative 2 PRISM project
(Psychiatric Ratings using Intermediate Stratified Markers).
P1vital Products Ltd | United
Kingdom http://www.p1vitalproducts.com
Jonathan Kingslake
+44 1865 522 030
EU SME INSTRUMENT PHASE 2
EU contribution 4.092.630 €
SOFTWARE FOR THE PHARMACEUTICAL AND
HEALTHCARE SECTORS
P1vital® Products Ltd provides innovative evidence-
based, digital health solutions for both the
pharmaceutical and healthcare sectors to improve the
treatment of mental and/or behavioural health
disorders.
6
Funded by the European Union
proACTINA SA is a research-driven and innovation-
focused clinical stage SME, founded in 2006 in Athens
-Greece. Through the establishment of successful
collaborations with the academia, industry and other
SME's, the company's activities focus on the
diagnostics / biomarker field; the “SME Instrument
Phase 2” grant awarded in 2015 further strengthens
the company’s position as a global player in this area.
Pro-ACTINA's vision is to become a leader in the
diagnostics for brain abnormalities by building in-
house expertise and by establishing strategic
collaborations for the development of novel non-
invasive diagnostic tools. Our mission is to provide
patients and doctors with innovative, cost-effective
diagnostic solutions as integrated parts of precision-
medicine approaches.
Our product:
proACTINA is currently partnering with both academia and
industry for the implementation of GLIOMARK, a “Horizon
2020” 4-year project for the clinical validation of an in vivo
biomarker for glioma (brain tumour) diagnosis. The end
product will consist of a diagnostic radiopharmaceutical kit,
containing the active substance tetrofosmin, for Single-
Photon Emission Computed Tomography (SPECT),
repositioned (by both clinical & pharmaceutical
development) specifically for brain imaging. This non-
invasive diagnostic technique will provide reliable glioma
diagnosis with high sensitivity & specificity aiming to
reduce the need for invasive and costly biopsy.
Clinical trial Phase II (ClinicalTrials.gov ID: NCT02971319)
results are expected Q3 2017; a Phase III clinical study will
follow Q1 2018. The end-product is expected to be ready
for Marketing Authorisation Application to EMA by 2021.
Other territories, including US, are being evaluated.
“Orphan Designation” has been granted by the European
Commission for tetrofosmin for the diagnosis of glioma
(EU/3/16/1764), thus ensuring 10 years of market
exclusivity in the EU. Orphan designation application to
FDA is being planned.
Our Unique Selling Points are the following:
1st Validated Imaging Biomarker for glioma diagnosis
Non-invasive solution for differential diagnosis &
grading of brain tumours
Promoting personalized treatment of glioma
patients worldwide
Repositioning of well-established diagnostic product
through the commercialization of a
Radiopharmaceutical kit for brain SPECT imaging
Orphan status granted in EU.
Our target audience:
pro-ACTINA is seeking to meet and discuss options with potential business partners in the US:
Investors in innovative life sciences projects, interested to invest funds for the completion of development of the existing radiopharmaceutical kit, as well as for further expanding the applications to several other brain tumor related indications.
Diagnostic/ Biotech companies (large or SMEs) to act as commercialization or co-development partners. They should have established networks to ensure efficient market penetration. Our company is flexible and open to discuss any type of collaboration with these business counterparts.
Companies with orphan therapeutic and/ or diagnostic products in their portfolio, to explore potential synergies and collaboration in various levels (co-development, co-marketing, exclusive rights for selected territories etc.).
Service providers to support further expansion of the current project in the US, such as regulatory experts with strong experience in diagnostic (radio)pharmaceutical development, consultants, imaging CROs in the US.
Why us:
proActina (along with project partner Consultech GmbH) received the European Union’s Horizon 2020 SME Instrument grant of €4.7M in 2015 (the only “Health” SME Instrument awarded grant in Greece).
proACTINA SA | GREECE
www.proactina.gr
Alexandros Strongylos
+30 2106 622 386
EU SME INSTRUMENT PHASE 2
EU contribution 4.705.344 €
GLIOMA BIOMARKERS & DIAGNOSTICS FOR BRAIN ABNORMALITIES
pro-ACTINA is pursuing the clinical and manufacturing
development of a novel, non-invasive, cost-effective
diagnostic tool for differential diagnosis of gliomas
(brain tumours).
7
Funded by the European Union
Abich S.r.l. is a SME providing research and analysis
for the industry, mainly manufacturers of cosmetics,
medical devices and other consumer products. Abich
offers a wide range of services in the field of
biological and chemical analysis to be applied in
cosmetics, biomedical, industrial hygiene, and other
sectors. Research activities are focused on the
development of new biotechnology–based methods
to assess the safety and effectiveness of industrial and
consumer goods such as chemicals, raw materials,
botanicals, cosmetics, medical devices, detergents
and textiles. ABICH has developed and implemented
many alternative in vitro assays to test the biological
properties and safety of products and ingredients for
human use.
Our product:
ABICH laboratories offer biological, chemical and clinical
testing and R&D projects in different industry sectors such
as cosmetics, drugs, medical devices, innovative textiles.
ABICH has developed and implemented a wide panel of
alternative in vitro assays based on cell cultures and
reconstituted tissues to test the safety and biological
properties of ingredients and products for human employ
(Toxicity assays, percutaneous absorption, efficacy assays).
Abich received a special innovation prize from the Italian
Chamber of Commerce in 2004.
Strong partnership with the Molecular and Cellular
Immunology Laboratory of the San Raffaele Hospital in
Milan gave also birth to a spin-off service testing
company (ALLTOX), setting up innovative testing methods
and research projects concerning allergies related to
consumer products. A partnership with a clinical CRO (Latis
srl in Italy) allows to design and conduct clinical trials for
drugs and medical devices.
ABICH laboratories are equipped with a state-of-the-art cell
culture facility, a fully equipped analytical chemistry
division, a microbiological laboratory, two clinical and
cosmetic testing facility and a laboratory dedicated to
product formulation & development.
ABICH owns a ISO 9001 quality system certified by TUV and
operates according to GLP standard certified (Italian Health
Ministry). Montreal site is FDA approved for Sunscreen
testing (SPF). All the facilities are undergoing the GMP
certification process in 2017 for chemical and
microbiological quality control of drugs.
Our target audience:
Manufacturers (or Subcontractors for manufacturing) of
cosmetics, topical drugs (especially sunscreens), topical
medical devices from USA and Canada.
Investors for developing and launching the innovative
formulation/products (business angels, private and
institutional investors).
Distributors of cosmetics, sunscreens, topical drugs and
medical devices based in USA or Canada interested in
distributing the innovative products/technology.
Why us:
Aside from receiving a European Union’s Horizon 2020 - SME Instrument grant of 50.000 €, ABICH was the partner of EU SMARTNANO project (Sensitive Measurement, detector and identification of engineered nanoparticles in complex matrix) FP7 - NMP.2011.1.3-1 - Contract n°280779.
ABICH is a qualified partner of EU Joint Research Center in Ispra (IT).
ABICH SRL | Italy
www.abich.it
Paola Bazzoni
+39 0323 586 239
EU SME INSTRUMENT PHASE 1
EU contribution 50.000 €
CELL CULTURES TO TEST THE SAFETY
Abich S.r.l. is an advanced chemical and biological
laboratory, providing research and analysis for the
industry, mainly manufacturers of cosmetics, medical
devices and other consumer products. Established in
2002 as a start–up initiative and it was awarded with
the National Price for the most innovative companies
in Italy.
8
Funded by the European Union
BBH Biotech Polska is a Polish company focused on
biotechnology and microbiology. Our mission is to
develop biotechnology as a discipline in Poland.
The main objective for our company is to become one
of the most innovative enterprises on the biotech
market and a leading biotech innovator in Poland. In
the 5 upcoming years, we want to launch one
production department, keep our R&D department
and establish a laboratory for young entrepreneurs to
help them develop their early-stage projects.
Our projects:
USONIPRO is our flag project that uses carefully adjusted
soundwaves to enhance recombinant protein production in
bacterial expression systems. By exposing the bacterial
cultivation to precise parameters of the sound wave we can
increase the protein yield from 30% to even 90% per
cultivation without any biological or chemical additives. So
far this technology has been tested on two different strains
of E. coli and one strain of S. cerevisiae.
Bee Venom for chemistry, therapeutics and cosmetics : BBH
Biotech finished the prototype of bee venom collecting
device. We also acquired all of the necessary certifications
as well as the quality evaluation of the bee venom. The
harvest in May and we are ready to sell the product to our
customers.
Alcohol aging is yet another project in BBH Biotech that
combines soundwaves, with the effects of microbial
metabolism. Exposing alcohols like whisky, brandy,
tinctures and other maturing liquors to soundwaves of a
specific wavelength and power we can significantly
decrease the time that is needed to bring up the full
flavour of such drink.
Additionally, our company can provide several services
such as:
Microbiological cultivation: cultivating bacteria, yeasts and
moulds in lab to semi-industrial scale
Analytics: chemical and microbiological analyses of a
variety of materials including cultivation media, plant
extracts, environmental samples and other
Microbiological screenings and isolation: isolating a
specific strain from a sample, e.g. an environmental sample
Managing biotech projects: our company helps scientists
and companies in managing their biotechnological
projects and training project teams in project
management basics.
Our target audience:
The type of a business partners we are looking for
regarding:
USONIPRO: Is from Europe or the USA, produces and sells
biopharmaceuticals, is not a Contract Manufacturer
Organization, uses Escherichia coli or Pichia pastoris in its
production process, preferably produces a protein which is
secreted to production medium and a part of its yield is
stuck in the periplasmic space of a used microorganism,
Preferably is developing a new biopharmaceutical and is
planning to introduce it to the market.
Bee Venom: Uses bee venom or any of its components in
their production and is interested in long term contracts.
Alcohol aging: Produces maturing liquors, is open to new
methods and technologies and is willing to help furtherly
improve this kind of technology.
Why us:
As only a 4-year-old company, BBH Biotech has been
awarded a INNOTECH grant for highly innovative
technologies, a distinction by Hello Tomorrow Global
Summit committee in Paris (top 500 start-ups), and a
European Union’s H2020 SME Instrument grant of 50.000€.
BBH Biotech has also been chosen as a microbiological
contractor in a project from the National Science Center,
Poland and was invited to an international consortium for
ERACoBioTech program by Liverpool John Moores
University.
BBH Biotech Polska | Poland
www.bbhbiotech.com
Mateusz Hoppe Leszek Broniarek
+48 512 866 673
EU SME INSTRUMENT PHASE 1
EU contribution 50.000 €
INCREASES PROTEIN YIELD FROM A SINGLE
CULTIVATION FROM 30% TO 90%
USONIPRO – ultrasonic enhancement for protein
production - is a new alternative method, for
reclaiming recombinant proteins from bacteria.
9
Funded by the European Union
IONOVOTION markets a new generation of
oligonucleotides allowing an easy cellular membrane
transfer due to a covalently bound molecular delivery
structure. Furthermore efficacy and toxicity tests for
new drug candidates are provided, that are: rapid,
sensitive, and affordable.
Our product:
Ionovation's IonoChem product and service line is focussed
on the chemical modification of drug candidates to
optimise their biodistribution and cellular membrane
transfer.
Many drugs are designed to target molecules inside cells.
Due to the hydrophobic nature of the cell membranes
however not all types of drugs can enter the cells
satisfactorily – especially negatively charged
oligonucleotides require a delivery system to reach the
inner part of the cell. Established nanoparticular
oligonucleotide delivery systems deliver the substances
mainly to the liver. Ionovation's proprietary IonoChem
technology provides a novel and highly effective solution
to this problem by adding lipophilic tails directly to
molecules, which allows them to pass through membranes,
thus increasing bioavailability, by exploiting unique
properties on the nanoscale. Ionovation holds the central
patent family PCT/EP2013/069936 for this technology.
Ionovation's IonoTec product line offers instrumentation,
consumables, and services centred around membrane
biophysics with instruments for the automated
reproducible, and hence routine oriented generation of
lipid bilayers for the analysis of biomembrane related
phenomena. IonoTec thereby helps to investigate the
IonoChem delivery technology and offers the possibility to
effectively monitor drug optimisation.
Our target audience:
Our main motivation is for finding potential clients:
medium and large pharmaceutical and biotech companies,
academic labs and institutes developing potential
treatments against cancer, infectious, metabolic or age
related diseases on the basis of oligonucleotides.
We are also interested in setting up research and
distribution partnerships.
INOVOTION will set up offices in the USA in the years to
come. Thus, we are also interested in discussions with
economic regional agencies including New York,
Washington and California as well as investors to further
develop the technology and start a clinical pipeline.
Why us:
Ionovation received a European Union’s Horizon 2020 SME
Instrument grant of 50.000€ and was recognized as one of
the leading German technology development companies
through various highly competitive national and
international funding programs.
Ionovation GmbH | Germany
www.ionovation.com
Karsten Gall
+49 541 9778 660
EU SME INSTRUMENT PHASE 1
EU contribution 50.000 €
DRUG OPTIMISATION AND INTRACELLULAR DELIVERY OF
OLIGONUCLEOTIDES
Founded in 2004, Ionovation represents a wealth of
experience in the modification of biomolecules to optimise
biodistribution and allow transfer of cellular membranes. We
now focus on the molecular delivery of oligonucleotides with
their high therapeutic potential and are looking for
developmental partners and investors.
10
Funded by the European Union
Chronic pain affects over 100 million Europeans (WHO
2006-2016) and is one of the most under recognised
and under-treated medical problems of the 21st
century. Persistent pain seriously reduces quality of
life for millions of sufferers and tears at the economic
and social fabric of our culture. Chronic pain is
defined as an unpleasant sensory and emotional
experience lasting longer than three months and is
the leading cause of disability in the work place.
Chronic pain includes fibromyalgia, migraine/cluster
headache, back pain, TMD, osteo- and rheumatoid
arthritis, cancer pain, inflammatory muscle pain, and
neuropathic pain. On average, according to the WHO,
people live with their chronic pain for 7 years.
Since chronic pain is debilitating and affects most
aspects of life, chronic pain sufferers are strongly
motivated and will go to extreme lengths in order to
become pain free.
Our mission is to introduce and implement the SET
solution to the world and in the process solving
chronic pain issues for millions of people.
Our product:
With real data from large groups of patients, Kleinklein,
GmbH can for the first time ever characterize the
autonomic nervous system, which is depreciated in chronic
pain patients, and use it to fight chronic pain.
Using data, Kleinklein will be able to make real progress on
this large social problem. By iterating, continuing to add
data, measuring results, and adjusting and further
personalizing approaches, Kleinklein can attack chronic
pain and make people pain free. The stimulation raises BRS,
which is diminished in chronic pain patients. SET combines
this stimulation with operant behavioural therapy to put in
place healthy behaviours.
The therapy practices healthy adaptive instead of pain
behaviours. The operant approach is to learn by doing
rather than directly attempting a cognitive change (CBT).
The standard treatment requires 10 double sessions over 5
weeks (20 hours) with a behavioural therapist. A therapist
and patient E-learning program defines the protocol,
session by session, and tracks patient exercises.
The SET device ‘Impuls’ collects baroreceptor sensitivity
(BRS-a chronic pain biomarker), blood pressure, muscle
tension, patient history, patient standardized
questionnaires, and other patient data in a central cloud
server. This intelligent, learning, database supported pain
treatment model will revolutionize chronic pain treatment
by:
individualizing each patient’s treatment protocol
adjusting the treatment based upon patient
progress. A recent University of Marburg RCT study
with 65 patients showed a significant decrease of
pain severity (MPI) after SET in comparison to control
groups (p>0.001), an increase of BRS, and an
increase of heart rate variability (HRV) with most of
the patients becoming pain free
Our target audience:
It will be a launch point for introduction of the product into
the US and likely other countries outside of the EU.
This matches with our methods of market introduction and
education - we basic have a franchise model - fit perfectly
with the American market. We had a number of
conversation at the IAFP, International Association for the
Study of Pain, with American professionals, including
administrators and professors at UNC - University of North
Carolina, UCLA - Los Angeles, and the University of
Washington. We have confirmed that these organization
will have representatives at the trade fair.
Why us:
Kleinklein received a European Union’s Horizon 2020 SME
Instrument grant of 50.000€
KleinKlein, GmbH | Germany
http://kleinkleingmbh.de
Marc Mathys
+49 838 291 104 60
EU SME INSTRUMENT PHASE 1
EU contribution 50.000 €
CHARACTERIZE THE AUTONOMIC NERVOUS
SYSTEM
Interested in providing treatment to chronic
disease. Like Chronic pain includes fibromyalgia,
migraine/cluster headache, back pain, TMD,
osteo- and rheumatoid arthritis, cancer pain,
inflammatory muscle pain, and neuropathic pain.
11
Funded by the European Union
MikroBiyo was founded as a spin-off from Middle East
Technical University MEMS Center, Turkey in 2015.
MikroBiyo develops microfluidic and lab-on-a-chip
systems for biomedical applications. MikroBiyo’s main
product is a Circulating Tumour Cell (CTC) detection
system for early diagnosis and prognosis of cancer.
The company has received seed investment from the
European Investment Fund for prototype
development, and looking for Round A investment for
analytical and clinical validation, certification, and
commercialization stages.
The company has expertise on microfluidic device
design, electrical manipulation of cells, electronics-
based spectroscopy techniques, light microscopy
(visible and fluorescent), surface functionalization,
microfluidic experimentation, and microfabrication.
Mikro Biyo offers technologies on: CTC detection and
isolation, and drug resistance investigation for
precision medicine for early diagnosis and prognosis
of cancer.
Our product:
MikroBiyo develops tagCTC, a Circulating Tumour Cell
(CTC) detection system for early diagnosis and prognosis of
cancer, with a competitive edge on performance, cost, and
time-to-result. tagCTC is a stand-alone system, composed
of a small foot-print analysis unit with a future-proof
design and plug-and-play disposable microfluidic sterile
cartridges. The system stands out among its competitors
with the features of remarkable enhancement on recovery
rate and purity, prompt cell count and clustering
information, and collection of viable cells at the output,
within a process time <1h.
Our target audience:
As a newly founded start-up, MikroBiyo aims to develop
collaborations with possible business partners, including:
Hospitals/Clinics: MikroBiyo aims to initialise the clinical
validation studies in 2019. In that sense, possible
collaborations with doctors, hospitals and clinical research
organisations are sought, for multi-central clinical studies in
Europe and US. The data will be used for CE mark and FDA
applications before market launch.
Microfluidic companies: MikroBiyo looks for business
partners for the volume manufacturing of its product, in a
cost-effective manner. Collaboration with MEMS foundries
and polymer-based microfluidic foundries that meet the
requirements of MikroBiyo can be developed, from all
around the world, during Bio2017 meeting.
Investors: MikroBiyo seeks Round-A investment for product
development and design freezing. In that sense, the
company wants to use the opportunity to present itself and
its technology, and increase its recognition by investors
interested in CTC detection technologies.
Consultancy Firms: MikroBiyo wants to collaborate with
Clinical Research Organisations (CROs) in Europe and US
for consultancy and collaboration on clinical study design
for CE and FDA approval processes. MikroBiyo also wants
to get consultancy during commercialisation of its CTC
detection platform, especially for the regulatory issues for
IVD devices and reimbursement issues.
Pharma companies: Pharma companies can be an
alternative market segment for MikroBiyo’s CTC isolation/
detection platform. Pharmaceutical companies can use the
platform for industrial research for drug development using
CTCs as the target cells or they may carry out clinical
studies and evaluate the treatment outcome via CTC count
as a prognostic biomarker.
Why us:
MikroBiyo has received 2.1M € seed investment and further
raised 550k € through research project funds including
TÜBİTAK (TR) and a European Union’s H2020 SME
Instrument grant of 50.000€. The company holds two triatic
patents on microfluidics, and has a state-of-the-art
infrastructure for microfluidic design and testing.
Mikro Biyosistemler AŞ | Turkey
Özge Zorlu
www.mikrobiyo.com.tr
+90 312 285 05 30
EU SME INSTRUMENT PHASE 1
EU contribution 50.000 €
MICROFLUIDICS FOR CANCER DIAGNOSTICS
MikroBiyo develops tagCTC, a Circulating Tumour Cell
(CTC) detection system for early diagnosis and
prognosis of cancer, with a competitive edge on
performance, cost, and time-to-result. The company
plans to commercialize its product family starting
from 2020.
12
Funded by the European Union
Oakbio is a “Carbon Capture and Utilization/
Conversion” (CCU) company. Our Vision is to
profitably convert CO2 and other green house gases
(GHGs) into valuable products. Unlike other
companies who are producing relatively low value
biofuels, Oakbio is focused on renewable products
that are inherently valuable and profitable in and of
themselves, with or without a carbon tax or subsidy.
Oakbio’s core competency is its deep understanding
of microbial metabolism and pathways, and its proven
technology platforms. Oakbio’s business model is to
partner with established industrial businesses to
develop low capex/opex carbon capture and
utilization bio-factories based on Oakbio’s core
technologies.
Our product:
Oakbio makes several product families. Underneath all of
them is our unique CO2 to products bacterial conversion
platform which can be used to make chemicals, plastics
and animal feed and which can be used for industrial
production of many products from commodity chemicals,
to feed products to pharmaceuticals.
Currently we produce n-butanol, a biofuel and chemical
feedstock, PHA bioplastics, and animal feed products
targeted at the aquaculture market.
Our target audience:
Oakbio is looking for 5 types of business relationships
which are key to enablement and scale of our technology.
These are:
Partnership with CO2 or waste gas producers
Partnerships with Hydrogen, or syngas producers
Off-take agreements for our products
Joint ventures, licensing, co-development
partnerships.
Funding for Pilot, R&D
Why us:
OakBio has received a European Union’s Horizon 2020 SME
Instrument grant of 50.000€ and has won the CCEMC
Grand Challenge. And the CEC (California Energy
Commission) PIER grant. applications.
Oakbio LTD | United Kingdom
Brian Sefton
www.oakbio.com
+1 888 591 94 13
EU SME INSTRUMENT PHASE 1
EU contribution 50.000 €
CO2 TO BIOPRODUCTS COMPANY ENABLING
COVERSION OF GREEN HOUSE GASES INTO
VALUABLE PRODUCTS
Oakbio develops microbe strains and processes for
the conversion of CO2 and other gases into a wide
variety of products. . Our technology can be used to
produce commodity, fine and specialty chemicals,
enzymes and biologicals.
13
Funded by the European Union
Pharmahungary Group is a group of spin-off
companies from the academic research groups of
Prof. Peter Ferdinandy. Since their foundation from
2001, Pharmahungary Group has been involved in
over 200 preclinical and clinical development projects
with excellent records of client satisfaction regarding
quality, timeline, and budget. Pharmahungary clients
include TOP10 pharma companies, start-up biotech
companies, and university research tech transfer
offices as well. Furthermore, Pharmahungary develops
drug candidates and diagnostic tools for
cardiovascular diseases.
Our products:
1. Preclinical R&D services: innovative and cost effective
preclinical models from cells to large animals (including e.g.
farm pigs, mini pigs, dogs) in cardiovascular (e.g. infarct
size, heart failure, circulatory shock, stroke), metabolic (e.g.
diabetes, hyperlipidemia, atherosclerosis, obesity), and
renal disease models. Furthermore, animal models are
available for testing medical devices, drug-device
combinations, combination products, and Advanced
Medicinal Therapeutic Products as well. All preclinical
models include protocol development to maximize success
rate of studies.
2.Clinical R&D services: full service in clinical phase of
development including essential document preparation
including protocol writing, competent authority/ethics
committee submission, full management of clinical trials,
and CE marking of medical devices and In Vitro
Diagnostics. Special expertise in clinical trials with biologics,
Advanced Medicinal Therapeutic Products, medical devices,
and their combination products, managing Investigator
Initiated Trials, and niche trials that need strong scientific
and regulatory support.
3. In-house R&D projects: drug development projects (i.e.
Biglycan therapy, ProtectomiR, and MMP inhibitors) and
novel supporting technologies (i.e. SME Instrument Phase I
winner novel in vitro diagnostic technology platform
Infarnosys) developed by Pharmahungary Group are open
for out-licensing, co-development, and investment
opportunities. Pharmahungary Group can further develop
all in-house technologies up to Phase II, where investors
can exit.
Our target audience:
Pharmahungary Group as a global provider of innovative
preclinical and clinical R&D services is seeking long-term
collaborations in R&D projects, as well as smaller step-by-
step preclinical and clinical studies.
We intend to meet the following types of potential
business partners:
Business partners for preclinical R&D services: small,
medium sized biotech, and large pharma companies with
innovative drug candidates, medical devices, drug-device
combinations that are interested to out-source their
preclinical development from cells to large animals to a
cost-effective and high quality contract research
organisation (CRO).
Business partners for clinical R&D services: our typical
business partners are medical device, combination
products or drug development and manufacturing
companies that are in the clinical stage of product
development. We are interested to provide full clinical R&D
service in Central-Eastern Europe including e.g. CE marking
of medical devices, In Vitro Diagnostics, and Investigator
Initiated Trials.
Investor/co-development partner for in-house R&D
projects: we are looking for big pharma and/or investor
partners to out-license, co-develop, and invest in our early
stage in-house R&D projects including our SME Instrument
Phase I winner novel in vitro diagnostic technology
platform Infarnosys.
Why us:
Several successful grant applications including e.g. National
Heart Program from the Research, Development, and
Innovation Office of Hungary. Pharmahungary Group
received a European Union’s H2020 SME Instrument grant
of 50.000€.
Pharmahungary Group | Hungary
Peter Ferdinandy www.pharmahungary.com
+36 1242 76 43
EU SME INSTRUMENT PHASE 1
EU contribution 50.000 €
PROVIDER OF INNOVATIVE PRECLINICAL AND CLIN-
ICAL R&D
To provide innovative and cost-effective preclinical and
clinical R&D services with strong scientific support and
to co-develop diagnostics and therapeutics in cardiovas-
cular and metabolic diseases.
14
Funded by the European Union
simfo GmbH is specialized in cancer diagnostics. Its
analytical microscopic platform maintrac was
developed since 2005 together with the University of
Jena.
maintrac is able to detect and characterize vital
circulating tumor cells (CTC) at an early stage, even in
primary cancer patients, and with high sensitivity
compared to other diagnostic tools. simfo wants to
enable the responsible oncologist to select, adapt and
improve the therapeutic strategy in real time.
Numerous scientific articles have been published
since 2005 strengthening the scientific credibility of
maintrac. Today maintrac is already used frequently
from practitioners all over the world in their daily
routine. The objective of the maintrac CTC analysis
and its affiliated techniques is to deliver precision
medicine for cancer patients, that patients receive the
appropriate therapy at the right time.
Our product:
The highly sensitive microscopic quantification of CTC with
maintrac allows the assessment of tumor activity. maintrac
CTC assays are used to initiate treatments adequately to
cancer characteristics and to replace ineffective treatments.
After cancer remission, CTC counts serve as a tool for long-
term monitoring to identify potential relapse for immediate
action.
Until today maintrac CTC assays have achieved clinical
proof in more than 600 patients analysed in 13 clinical trials
with an observation period of up to 10 years. Clinical data
exists for different entities while the focus lies on breast
cancer in adjuvant, neoadjuvant and maintenance therapy.
In addition, we have performed more than 80.000 tests
from patients worldwide until 2016.
simfo GmbH has developed the first high-throughput
analyser prototype for CTC biomarker analyses which
allows processing approx. 400 patient samples per day with
an excellent specificity and sensitivity profile not yet
achieved so far by other competing CTC systems.
Our target audience:
Biotech and pharma companies with R&D programs and a
product pipeline of cancer therapeutics. maintrac can
identify and quantify target structures on CTC in very early
cancer stages even if biopsies are not possible. Treatments
can be adapted in real time to the patient’s individual
situation.
Distribution partners with contacts and knowledge in the
field of cancer diagnostics and corresponding regulatory
issues.
Investors with profound knowledge about the cancer
diagnostics market in Northern America..
Academics interested in cancer stem cell research and
clinical trial as well as cancer specialists interested in cancer
diagnostics in general.
Why us:
Apart from being a finalist in the "Businessplan
Wettbewerb Nordbayern" in 2013, simfo was the winner of
several prizes including poster prizes (DGHO 2013) and
oral presentation awards (COSA 2014). Futhermore we
received several German grants for CTC and cancer stem
cell research. simfo GmbH has received a European Union’s
H2020 SME grant of 50.000€.
SIMFO GmbH| Germany
www.simfo.de www.maintrac.com
Dr. Stefan Schuster
+49 921 730 052
EU SME INSTRUMENT PHASE 1
EU contribution 50.000 €
BIOMARKERS AND LIQUID BIOPSY APPROACH
simfo’s product maintrac is a versatile cancer diagnostic
platform to identify and characterize circulating tumor
cells with a high sensitivity, even in primary cancer pa-
tients. Up to now, more than 80.000 tests were performed
in clinical trials and clinical routine to monitor and opti-
mize cancer treatment.
Living (green) and dead (green and red) CTC
Maintrac automated prototype
15
Funded by the European Union
SPARK-TECH sp. z o.o. is a biotechnology company
incorporated in 2015 and dedicated to conduct R&D
for developing innovative solutions, to overcome
essential limitations of existing medical and research
technologies. The company is based on a fast
growing, high-skilled team, with centralized but
collaborative governance which promptly
accomplishes both decision-making and actions.
Our flagship product the Spark Tube Biobanking
System (STBS) was invented to address several
important roadblocks in separation, preservation and
biobanking of human blood. Spark-Techs’ technology
is based on patent pending highly advanced
innovations. Major markets for STBS include: safety
and efficacy monitoring for public health and
pharmaceutical industry; secondly, medical diagnostic
biomarkers for cancer, neurodegeneration,
cardiovascular diseases; thirdly, epidemic outbreak
and rare diseases treatment for WHO and military
(Ebola, Zika viruses).
SPARK-TECH is currently funded by the EU within SME
Instrument and OFT program. To accelerate its
development and market entry, the company is
looking into national grants opportunities, and
industrial partnerships, as well as investors.
Our product:
We are a start-up company, SBTS and its components are
our most developed products.
STBS is the first commercially available automated system
for separation, preservation and biobanking of human
blood. Major advantages of the system are high-
throughput sample processing, cost-effective design,
environmentally friendlily product combined with fully
operated hands-off processes.
Spark Separation Tube which will enter market in the third
quarter of 2017 is the first element of STBS. Thanks to its’
innovative and patent pending construction, it allows for
automated highly repetitive and accurate process of
layering liquids by creating sharp interphase between
them. Automatization enables blood separation to fractions
high-throughput, highly repetitive, easy-to-handle and
human error free.
Our other products include:
Competitive and affordable fast laser systems for
biomedical research and diagnostics such as microscopy,
gene-expression profiling or cytometry.
Novel portable and adjustable hypoxic chamber for
medical diagnostics and research applications.
Our target audience:
Customers in need for: automatic separation of blood to
fractions, high-throughput preservation of blood or cells
and long term storage of blood based material.
Companies, research entities, organizations conducting:
clinical trials, blood based biomarkers testing, cord blood
bio-banking service.
Partners: interested in adopting our automatized and high-
throughput solutions for blood separation, preservation
and storage in their products to increase accuracy and to
reduce human error.
Companies, research entities: specialized in DNA and/or
RNA service/reagents (RNA/DNA isolation, purification,
gene expression profiling, RNA/DNA sequencing);
specialised in blood based cell services/reagents (blood cell
isolation, blood cell assays, blood cell phenotyping, blood
cell based treatment); providing support, software and
equipment for bio-banking industry.
Industrial Partners and Investors: interested in investing
their expertise and capital to support our product in terms
of further development, miniaturization, scale-up,
obtaining CA and FDA approvals, advertising and
distribution.
Companies, research entities, organizations: specialized in
IT software for bio-archiving; specialized in engineering
(low temperature technologies, freezer storage systems);
with established biomedical distribution and marketing
channels.
Why us:
Spark-Tech received a European Union’s Horizon 2020
SME Instrument grant of 50.000€, and was further selected
from SME Instrument champions to participate in BIO 2017
under Horizon 2020 Overseas Trade Fair program.
SPARK-TECH sp. z o.o. | Poland
www.spark-tech.eu
Dr Mateusz Adamski
+ 48 123 110 032
EU SME INSTRUMENT PHASE 1
EU contribution 50.000 €
AUTOMATED SYSTEM FOR FRACTIONING,
PRESERVING, AND BIOBANKING OF HUMAN BLOOD
Spark-Tech has developed the Spark Tube Biobanking
System (STBS). The first commercial automated, high-
throughput biobanking system with the ability to fraction
and preserve human blood. Spark Separation Tube -first
element of STBS- enables automated blood fractioning
and will enter the market in 2017.
16
Funded by the European Union
We have developed simple blood tests for cancers
detection, tests that are low-cost and accessible to
the mass population.
Unfortunately, cancer is a disease that has touched all
of our lives in some manner. What is known for
certain is that early detection of the disease is critical
to save lives at lower pain and cost. To this end,
TODOS Medical is focused on creating a new
methodology for cancer early detection that make
cancer detection at early stages more accessible and
affordable to the general public.
Todos Medical introduced two tests: TM-B and TM-C
(for breast and colon cancer detection) and plan to
enhance the number of tests in the future.
TODOS medical innovative technology (TBIA*) is
based on using the immune system (mononuclear
cells) as the sensor for the cancer existence and
utilizing advanced optical and mathematical tools for
generating the result enabling automated, operator
independent test for large amount of people world-
wide (patented).
Our product:
Our Technology (TBIA) is harnessing the immune system
for detecting cancer. Our immune system detect the cancer
existence at early stages and try to kill it, TBIA technology is
captechring this biochemical event and “spectral
fingerprint”. Our cancer screening process begins with a
simple and minimally intrusive blood test. Our method is
based on infrared spectroscopy measurements of the
blood sample and computerized analysis. The basic
concept of our technology is to measure the biochemical
changes in the peripheral blood mononuclear cells
(“PBMC”) and plasma, due to cancer presence. As the PBMC
are part of the body’s immune system, our methodology
will detect overall biochemical changes of the immune
system due to cancer presence. The technology involves
special infrared (“IR”) measurement of a simple blood
sample. The test uses conventional lab methods and the
mathematical analysis is made automatically by proprietary
algorithms.
TODOS Medical provides two tests and plans to enhance
the number of tests in the future.
There is a scientific consensus that many different
immune markers and biomarkers have to be taken into
consideration to detect cancer existence. Our approach
addresses this need since we check the total biochemical
construction on the PBMC and plasma.
Our target audience:
Commercial space: We are looking for partners to sell our
products.
Investors: We offer the option of investing in Todos
Medical at early stage and be part of our quest.
Pharma companies: We offer a tool to evaluate their drugs
influence on the immune system.
Researchers and research institutes: We offer a unique
innovative research tool for inspecting the immune system.
It is a new tool to explore emerging immunotherapy field.
Scientists and researchers can have an easy and fast access
to the immune system biochemical profile.
Why us:
Todos Medical won a grant from the EU SME Instrument
and from the Israeli Chief Scientist.
We have developed a unique innovative platform with
many opportunities to explore. Todos Medical has received
a European Union’s H2020 SME Instrument grant of
50.000€.
Todos Medical | Israel
www.todosmedical.com
Rami Zigdon
+972 8 633 3964
EU SME INSTRUMENT PHASE 1
EU contribution 50.000 €
BLOOD TEST FOR BREAST AND COLON CANCER
DETECTION
Todos Medical mission is to provide blood tests for early
detection of breast and colon cancers. The test is low cost
and simple to implement, creating an economically sound
method for early detection. These blood tests are targeted
to be the first choice of physicians to detect cancers. CE
Mark and US Patent 9,606,057
17
Funded by the European Union
Viomedo is the leading clinical trial platform in the
German-speaking DACH region. Thousands of
patients, their caregivers and doctors use it every day
in order to learn about their options within clinical
trials. Viomedo effectively accelerates your patient
recruitment in a scalable and effective way, helping
you to get to market faster.
Patients have access to up-to-date information on
over 2.000 clinical trials. Patient advocacy groups use
our information in order to help their members gain
access to new therapies. Doctors use Viomedo in
order to recommend clinical trials to their patients.
Caregivers access our platform, as they look for
treatment options for their loved ones.
Viomedo - tomorrow’s medicine, today.
Our product:
VIOMEDO-AR: ActiveRecruitment
Competitive pressure and ever more niche patient cohorts.
Patient recruitment is hard work and causes delays in most
studies. Viomedo is here to help and accelerate your time
to market. Using our exclusive distribution network and
patient database, we find patients that your sites would
never see. Our in-house medical team qualifies each
patient individually in order to assure eligibility and
motivation. We work closely with the investigator sites who
benefit from additional patients and our support. Our
software provides sponsors with transparency across the
process and investigators with a secure system to support
randomization.
VIOMEDO-ATL: AllTrialsLocal
Make all your trials accessible to local patients and the
healthcare ecosystem, by publishing them on Viomedo. We
distribute your trial information across our distribution
network to patient advocacy groups and publishers. You
benefit from additional patient referrals and analytics on
patient interests, site performance and study feasibility.
VIOMEDO-TD: TrialData
EHR vendors and laboratories can now access Viomedo’s
up-to-date data and matching system in order to provide
healthcare professionals relevant information on clinical
trials.
Our target audience:
Viomedo is reaching out to multinational and regional
pharma and biotech companies, CRO and industry
associations that conduct or support multinational clinical
trials.
Furthermore, Viomedo is interested in forming partnerships
with international patient advocacy organizations, EHR
vendors, laboratories and NGS genome sequencing
providers that are active in Europe.
Why us:
Viomedo has received several grants and awards from
Handelsblatt, Techniker Krankenkasse or Bayer
Pharma. Viomedo also received an European Union’s
H2020 SME Instrument grant of 50.000€.
Viomedo | Germany
www.viomedo.de
Alexander Puschilov
+49 30 220 125 62
EU SME INSTRUMENT PHASE 1
EU contribution 50.000 €
ACCELERATE PATIENT RECRUITMENT FOR YOUR
CLINICAL TRIALS
Viomedo's scalable patient recruitment solution matches the
right patient with your clinical trial by reaching new patients
through its online platform.The solution effectively
accelerates patient recruitment and has contributed up to
30% of additional patients to the participating sites.
Significantly increase the
number of randomized
patients per site
Only pay for the actual
patients we provide
Support your
investigators with
qualified patient referrals
Stay in control with full
transparency
